Lilong Liu

Dr. Lilong Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZYZhipeng Yao
Zhipeng Yao
YLYang Li
Yang Li
YDYuhong Ding
Yuhong Ding
YHYaxin Hou
Yaxin Hou
JHJunyi Hu
Junyi Hu
ZLZhen Li
Zhen Li
The advantages of en bloc resection of bladder tumors (ERBT) over transurethral resection of bladder tumors (TURBT) in terms of patient prognosis are not yet clear, and there are some technical limitations. We aimed to compare the tumor recurrence in non-muscle invasive bladder cancer (NMIBC) patients with tumor diameter ≥ 3 cm undergoing either TURBT or thulium laser ERBT. The patients included were those diagnosed with NMIBC based on pathological confirmation and underwent TURBT or modified thulium laser ERBT in the Department of Urology at Tongji Hospital from 2019 to 2024. The patients’ medical records were meticulously collected and postoperative follow-up was diligently conducted by trained personnel. Recurrence-free survival curves were generated utilizing the Kaplan–Meier method, and group comparisons were performed using the log-rank trend test. To minimize biases, we employed stratified survival analysis, alongside univariate and multivariate Cox regression analysis. This study included a total of 396 patients with NMIBC, with 214 undergoing TURBT and 182 undergoing ERBT. For all patients, there was no significant difference (P = 0.180) in RFS between the TURBT and ERBT groups. For patients with tumor diameter ≥ 3 cm, stratified analysis revealed that the RFS of the ERBT group was significantly better than that of the TURBT group (P = 0.033). However, in patients with tumor diameter < 3 cm, there was no significant difference (P = 0.150) between the two groups. Univariate (HR: 0.52, 95% CI 0.28–0.96, P = 0.036) and multivariate (HR: 0.49, 95% CI 0.25–0.93, P = 0.031) Cox analyses revealed that ERBT was an independent protective factor for recurrence in NMIBC patients with tumor diameter ≥3cm. This study found that thulium laser ERBT may offer advantages in managing NMIBC patients with tumor diameters ≥ 3 cm. This could potentially drive the clinical application of thulium laser ERBT. Protocol was registered at Chinese Clinical Trial Register (ChiCTR) with number ChiCTR2000035407 on 12 August 2020.

24 May 2024 in International Journal of Surgery
Verified
Journal Article
Open access
LLLilong Liu
Lilong Liu
KLKaiwen Li
Kaiwen Li
Shaogang WangShaogang Wang
Shaogang Wang
CCChinese Bladder Cancer Consortium
Chinese Bladder Cancer Consortium
JWJianli Wang
Jianli Wang
KCKe Chen
Ke Chen
Objective: Most bladder cancers are nonmuscle invasive bladder cancer (NMIBC), and transurethral resection of bladder tumors (TURBT) is the standard treatment. However, postoperative recurrence remains a significant challenge, and the influence of bladder tumor location on prognosis is still unclear. This study aims to investigate how tumor location affects the prognosis of NMIBC patients undergoing TURBT and to identify the optimal surgical approach. Methods: A multicenter study was conducted, which included Chinese NMIBC data from 15 hospitals (1996–2019) and data from 17 registries of the Surveillance, Epidemiology, and End Results database (SEER) (2000–2020). Patients initially diagnosed with NMIBC and undergoing TURBT or partial cystectomy were analyzed, with cases lost to follow-up or with missing data excluded. The study investigated the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) among patients with different tumor locations. Kaplan–Meier, Cox regression, and propensity score matching methods were employed to explore the association between tumor location and prognosis. Stratified populations were analyzed to minimize bias. Results: This study included 118 477 NMIBC patients and highlighted tumor location as a crucial factor impacting post-TURBT prognosis. Both anterior wall and dome tumors independently predicted adverse outcomes in two cohorts. For anterior wall tumors, the Chinese cohort showed hazard ratios (HR) for OS of 4.35 (P<0.0001); RFS of 2.21 (P<0.0001); SEER cohort OS HR of 1.10 (P=0.0001); DSS HR of 1.13 (P=0.0183). Dome tumors displayed similar trends [Chinese NMIBC cohort OS HR of 7.91 (P<0.0001); RFS HR of 2.12 (P<0.0001); SEER OS HR of 1.05 (P=0.0087); DSS HR of 1.14 (P=0.0006)]. Partial cystectomy significantly improved the survival of dome tumor patients compared to standard TURBT treatment (P<0.01). Conclusion: This study reveals the significant impact of tumor location in NMIBC patients on the outcomes of TURBT treatment, with tumors in the anterior wall and bladder dome showing poor post-TURBT prognosis. Compared to TURBT treatment, partial cystectomy improves the prognosis for bladder dome tumors. This study provides guidance for personalized treatment and prognosis management for NMIBC patients.

27 November 2024 in Genes
Verified
Journal Article
Open access
PDF file
LLLilong Liu
Lilong Liu
ZYZhipeng Yao
Zhipeng Yao
YLYiting Liu
Yiting Liu
YLYang Li
Yang Li
YDYuhong Ding
Yuhong Ding
YHYaxin Hou
Yaxin Hou
Objectives: B7 homolog 3 protein (B7-H3, also known as CD276) is a member of the B7 family that has been found to be associated with the growth and progression of a variety of tumors, but no pan-cancer evaluations of CD276 have been performed so far. In this study, we aimed to perform a pan-cancer analysis of the oncogenic role of CD276 in human tumors; Methods: We used a series of databases to perform a pan-cancer analysis of CD276, including the expression level of CD276 in pan-cancer and its relationship to tumor progression, patient survival duration, the immune cell infiltration within the tumor, and the potential signaling pathways and molecular mechanisms associated with CD276; Results: We found that CD276 was a potential biomarker for the prognosis of most cancers. The high expression of CD276 was associated with tumor progression, leading to poor survival. Notably, the up-regulation of CD276 expression in tumors increased the tumor infiltration of cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs) and decreased the CD8+ T cells; Conclusions: Our study demonstrates that CD276 might promote tumor progression via the promotion of an immunosuppressive microenvironment.

6 February 2025 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
JWJianli Wang
Jianli Wang
DCDiansheng Cui
Diansheng Cui
YZYuancheng Zhou
Yuancheng Zhou
HBHaibin Bao
Haibin Bao
JCJiawei Chen
Jiawei Chen
LLLilong Liu
Lilong Liu

31 December 2025 in European Urology Open Science
Verified
Journal Article
Open access
YLYixian Li
Yixian Li
ZLZongyu Li
Zongyu Li
HLHongxia Lu
Hongxia Lu
PSPengjie Shi
Pengjie Shi
YLYiting Liu
Yiting Liu
KCKe Chen
Ke Chen
Olaparib is one of the earliest approved treatment options for metastatic castration-resistant prostate cancer (mCRPC). This systematic review and network meta-analysis aimed to determine the optimal olaparib strategy for treating mCRPC. The Cochrane, Embase, PubMed, and Web of Science databases were searched comprehensively using “mCRPC” and “olaparib” as keywords. Study quality was appraised with the National Institutes of Health tools. Data were analyzed in R version 4.4.1. The primary endpoints included progression-free (PFS) and overall (OS) survival. The secondary endpoints included adverse events and severe adverse events (grade ≥3). Effect sizes were reported as hazard ratios (HRs) and risk ratios, with 95% credibility intervals (CrIs). Nine studies from seven clinical trials involving 2355 patients were identified. For homologous recombination repair–mutated mCRPC, combination therapies did not demonstrate significant benefits compared with olaparib alone. However, for BRCA-mutated mCRPC, olaparib combined with abiraterone improved PFS (HR = 0.61, 95% CrI = 0.41–0.91) and OS (HR = 0.41, 95% CrI = 0.21–0.80) significantly. These significant advantages of olaparib combined with abiraterone were also observed in patients from different prostate-specific antigen subgroups. These findings suggest that olaparib combined with abiraterone offers substantial benefits in BRCA mutated type (BRCAmt) mCRPC patients. For those with BRCA wild type homologous recombination repair–mutated mCRPC, olaparib monotherapy is effective. We reviewed the published studies comparing different treatment options using the drug olaparib (alone or combined with other therapies) for advanced prostate cancer that has spread and no longer responds to standard hormone therapy (metastatic castration-resistant prostate cancer). We found evidence that the effectiveness of olaparib depends significantly on specific genetic features of the cancer. For patients whose cancer has changes in the BRCA genes, the combination of olaparib and the drug abiraterone was more effective in delaying cancer growth and improving survival than olaparib alone. For patients with changes in other related DNA repair genes (but not BRCA), olaparib alone was an effective treatment. This information may assist doctors and patients in choosing the most suitable treatment based on the cancer’s genetic characteristics.

27 August 2025 in Cancer Research
Verified
Journal Article
Closed access
YDYiheng Dai
Yiheng Dai
LLLilong Liu
Lilong Liu
YLYongbo Luo
Yongbo Luo
CZCai Zhang
Cai Zhang
SXSayu Xiao
Sayu Xiao
LZLijie Zhou
Lijie Zhou
Malonyl-CoA, a key metabolite, is not only the building block for lipogenesis but also a critical regulator of mitochondrial fatty acid β-oxidation. Given the altered metabolic state of many cancers, malonyl-CoA may play a role in tumor development and drug resistance, especially in malignancies characterized by abnormal lipid metabolism, such as prostate cancer. In this study, we showed that the levels of malonyl-CoA were increased in prostate cancer, especially in castration-resistant prostate cancer. Abnormal accumulation of malonyl-CoA promoted lipogenesis and regulated metabolic processes, maintaining endoplasmic reticulum homeostasis and mitochondrial function and ultimately contributing to prostate cancer progression. Restoration of malonyl-CoA decarboxylase expression activated the unfolded protein response via the consumption of malonyl-CoA. Importantly, malonyl-CoA accumulation promoted lysine malonylation in prostate cancer. Ran K141 malonylation increased Ran activity and enhanced androgen receptor nuclear translocation and transcriptional activity, ultimately contributing to prostate cancer development and resistance to antiandrogens. These findings highlight the function of malonyl-CoA in prostate cancer progression by regulating metabolic processes and malonylating Ran K141, revealing that the malonyl-CoA axis might be a reliable biomarker and a potential therapeutic target in prostate cancer. Significance: Malonyl-CoA induces metabolic reprogramming and Ran-mediated androgen receptor activation to support prostate cancer development and drug resistance, providing a mechanism that could be harnessed for developing treatment strategies for advanced prostate cancer.